Aspire Biopharma Holdings (ASBP) Cash & Equivalents (2022 - 2026)
Aspire Biopharma Holdings (ASBP) posted quarterly Cash & Equivalents of $1.8 million for Q1 2026, up 35.66% year-over-year from $1.3 million in Q1 2025, and up 35.66% quarter-over-quarter from $1.3 million in Q1 2025.
Aspire Biopharma Holdings (ASBP) Cash & Equivalents (2022 - 2026) Analysis & Trends
Aspire Biopharma Holdings (ASBP) has reported Cash & Equivalents for 5 consecutive years, with $1.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash & Equivalents rose 35.66% year-over-year to $1.8 million; the TTM figure through Mar 2026 stood at $1.8 million (up 35.66% YoY), while the FY2024 annual figure was $3633.0, down 67.49% from the prior year.
- Cash & Equivalents climbed to $1.8 million in Q1 2026 per ASBP's latest filing, from $1.3 million in the prior quarter.
- Across five years, Cash & Equivalents topped out at $1.8 million in Q1 2026 and bottomed at $3633.0 in Q4 2024.
- Historically, Cash & Equivalents has averaged $484578.2 across 5 years, with a median of $406205.5 in 2022.
- Annual changes were most pronounced in 2023 — Cash & Equivalents plunged 97.75% — and 2025, when it surged 2747.6%.
- Aspire Biopharma Holdings' Cash & Equivalents stood at $497259.0 in 2022, then slumped by 97.75% to $11174.0 in 2023, then tumbled by 67.49% to $3633.0 in 2024, then soared by 36964.22% to $1.3 million in 2025, then soared by 35.66% to $1.8 million in 2026.
- Business Quant data shows ASBP's Cash & Equivalents at $1.8 million in Q1 2026, $1.3 million in Q1 2025, and $3633.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 3.58 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 1.72 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.71 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 8.93 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 544.80 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 811.99 Mn |
| 10 | Aspire Biopharma Holdings | 8.30 Mn | -3.86 Mn | -30,086.00 | 12.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.17 Mn |
| Mar 31, 2026 | 1.83 Mn |
| Mar 31, 2025 | 1.35 Mn |
| Dec 31, 2024 | 3,633.00 |
| Sep 30, 2024 | 16,541.00 |
| Jun 30, 2024 | 19,604.00 |
| Mar 31, 2024 | 47,287.00 |
| Dec 31, 2023 | 11,174.00 |
| Mar 31, 2023 | 315,152.00 |
| Dec 31, 2022 | 497,259.00 |
| Sep 30, 2022 | 533,129.00 |
| Jun 30, 2022 | 579,751.00 |
| Mar 31, 2022 | 618,122.00 |